In contrast to the combination of FAP-IL and pembrolizumab in this study in anti–PD-1–resistant melanoma, overall positive signals of activity were observed with the combination of FAP-ILv2 plus atezolizumab in CPI-naïve patients with oesophageal cancer (15), cervical squamous cell carcinoma (14), and renal cell carcinoma (17). This evidence concerns the gene FAP and hereditary clear cell renal cell carcinoma.